Table_1_Colonial drivers and cultural protectors of brain health among Indigenous peoples internationally.DOCX

Despite relatively higher rates of dementia among Indigenous populations internationally, research into drivers of disparities in brain health and cognitive function has tended to focus on modifiable risk factors over cultural understandings and contextual determinants. By seeking to characterize social and cultural factors that shape brain health and cognition in Indigenous populations, this mini scoping review expands prevailing schools of thought to include Indigenous knowledge systems. This reveals important gaps in culturally aligned care. It also reclaims horizons for research important to Indigenous Peoples that have garnered diminished attention in biomedical approaches. Twenty-three sources were included for data extraction. This synthesis of 23 sources includes health communication about dementia, health provider knowledge about Indigenous health, culturally relevant screening and assessment tools, and culturally grounded care models. Much of the focus is currently still on modifiable risk factors that reside at individual factors, whereas attention to wider social factors that impact populations is needed, as stressors through isolation, discrimination, and unequal care are widely reported. Going forward, identifying structural barriers to living well and recognizing the importance of connection to culture will benefit both Indigenous and non-Indigenous understandings of brain health.</p

MOESM1 of Two inhibitors of yeast plasma membrane ATPase 1 (ScPma1p): toward the development of novel antifungal therapies

Additional file 1: Table S1. A list of additional antifungal compounds found in our whole-cell screen. Figure S1. IC50 curves for the cell-free, vesicle-based ScPma1p assays. Figure S2. IC50 curves for the whole-cell assays. Figure S3. Compound IC50 values against whole-cell ABC16-Monster yeast, with and without two distinct spiroindolone-binding-pocket ScPMA1 mutations (L290S and P399T)

Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects

<div><p></p><p><i>Objective</i>: Autoantibodies directed against the two principal antigens of the human exosome complex, PM75 and PM100, are present in systemic sclerosis (SSc) sera and have been associated with myositis and calcinosis. However, there is a paucity of data on the clinical correlates of these autoantibodies separately and in the absence of other SSc-specific antibodies. The aim of this study was to assess the clinical correlates of monospecific anti-PM75 and anti-PM100 in SSc. <i>Methods</i>: A tri-nation cohort of 1574 SSc subjects was formed, clinical variables were harmonized and sera were tested for anti-PM75 and anti-PM100 antibodies using a line immunoassay. <i>Results</i>: Forty-eight (3.0%) subjects had antibodies against PM75 and 18 (1.1%) against PM100. However, only 16 (1%) had monospecific anti-PM75 antibodies and 11 (0.7%) monospecific anti-PM100 antibodies (i.e. in isolation of each other and other SSc-specific antibodies). Monospecific profiles of each autoantibody included more calcinosis. An increased frequency of myositis was only seen in subjects positive for both anti-PM75 and anti-PM100 antibodies. Lung disease was only associated with anti-PM75 and subjects with anti-PM100 antibodies had better survival compared to other antibody subsets. <i>Conclusion</i>: The prevalence of monospecific anti-PM75 and anti-PM100 antibodies in this large SSc cohort was low. Disease features associated with anti-PM/Scl antibodies may depend on particular and possibly multiple antigen specificities. However, due to the small samples, these results need to be interpreted with caution. International collaborations are key to understanding the clinical correlates of uncommon serological profiles in SSc.</p></div

Demographic and behavioural associations with prevalent bacterial vaginosis by univariate and multivariate analysis (n = 1093).

<p>a = odds ratio; b = multivariate analysis including: recent female sex partner, current use of oestrogen containing contraception, numbers of male sex partners, recruitment site (sexual health/family planning clinic or general practice clinic), education level achieved, tested positive for chlamydia at baseline; c = Identify as Aboriginal and/or Torres Strait Islander Origin; d = test for trend; * self-reported and note clinical symptoms are not included in any multivariate analyses.</p

Demographic and behavioural associations with incident bacterial vaginosis by univariate and multivariate analysis.

<p>a = rate ratio; b = multivariate analysis including: recent new male sex partner, current use of oestrogen containing contraception, currently employed, recruitment site (sexual health/family planning clinic or general practice clinic); c = Aboriginal and/or Torres Strait Islander origin. d = recent refers to within the 3 months prior to testing.</p

Chlamydia trachomatis serovars and genotypic variants detected in positive samples among a cohort of sexually active 16 to 25 year old women.

a<p> <b> = E variant has 100% homology to Genbank sequence GU903922 (C. trachomatis strain 1969 from Australian male population);</b></p>b<p> <b> = G variant has 100% homology to Genbank sequence FJ261928 (G/IU-FW0267);</b></p>c<p> <b> = N/A: serovar unable to be determined.</b></p

Algorithm to differentiate between chlamydia re-infection, treatment failure and persistent infection [adapted from Batteiger et al (2009)] [<b>6</b>].

<p>N/A = Serovar result not available.</p

Organism load per 100 cells during episodes of chlamydia re-infection^* among a cohort of sexually active 16 to 25 year old women.

*<p> <b>The time interval between the diagnoses was 3 to 6 months.</b></p>a<p> <b> = Excludes 2 people with missing organism load results.</b></p

Kaplan Meier curve showing proportion remaining uninfected with incident chlamydia infection over time among a cohort of sexually active 16 to 25 year old women.

<p>Kaplan Meier curve showing proportion remaining uninfected with incident chlamydia infection over time among a cohort of sexually active 16 to 25 year old women.</p

Kaplan Meier curve showing proportion remaining free from chlamydia re-infection over time among a cohort of sexually active 16 to 25 year old women.

<p>Kaplan Meier curve showing proportion remaining free from chlamydia re-infection over time among a cohort of sexually active 16 to 25 year old women.</p